PHPatrick Noel Angier Harris

Patrick Noel Angier Harris

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Patrick Noel Angier Harris has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Disruption of cAMP Signalling and RNA Regulation Confers Cefiderocol Resistance in Acinetobacter baumannii

    by David M. P. De Oliveira, Ruby Heaton, Hayden Whyte, Larissa Buedenbender, Anuk D. Indraratna, Nguyen Thi Khanh Nhu, Minh-Duy Phan, Saleh F. Alquethamy, Yujiro Hirose, Budi Permana, et al.

    Cefiderocol is a siderophore-conjugated cephalosporin used to treat severe multidrug-resistant Gram-negative infections. Its recent prioritisation for US national preparedness underscores its clinical importance, yet resistance can emerge despite apparent in vitro susceptibility. Here, we identify two regulatory routes to cefiderocol resistance in carbapenem-resistant Acinetobacter baumannii (CRAB): mutation of the cAMP-producing adenylate cyclase CavA and truncation of the glycine-rich RNA-binding domain of the post-transcriptional regulator Hfq. These variants occurred in contemporary clinical isolates, conferred resistance in a murine CRAB lung-infection model and imposed minimal fitness costs. In Escherichia coli , deletion of the CavA orthologue cyaA increased competitive fitness during sub-inhibitory cefiderocol exposure. Hfq-CLASH and integrated omics revealed Hfq-dependent regulation of Fur-associated iron homeostasis in A. baumannii. Under iron limitation, truncated-Hfq induced a defence-primed state that attenuated siderophore uptake and reduced cefiderocol activity. These findings identify bacterial regulatory state and iron availability as determinants of cefiderocol susceptibility, with implications for resistance surveillance and susceptibility testing.

  • Open Access

    Cross-species convergence of surface polysaccharides shapes the virulence of an atypical carbapenem resistant uropathogenic Escherichia coli clone

    by Lachlan L. Walker, Zheng Jie Lian, Minh-Duy Phan, Nguyen Thi Khanh Nhu, Yvette Yu Ting Ong, Vitus Brix, Adam N. Marin, Brian S. Learman, Budi Permana, Irene Martinez-Roman, et al.

    Carbapenem-resistant Escherichia coli (CREC) is an emerging global health threat associated with limited treatment options and increased mortality. Here, analysis of 20,331 E. coli genomes from urinary tract infection (UTI) and urine samples identifies phylogroup A sequence type 361 (ST361) as an emerging CREC clone associated with UTI. Phylogenetic and phylodynamic analyses reveal two dominant ST361 clades that emerged in Asia around 2006 and subsequently disseminated intercontinentally. ST361 exhibits near pan-drug resistance, with bla NDM-5 conferring carbapenem resistance. In silico capsule and O-antigen typing reveals a highly conserved Klebsiella -like surface polysaccharide serotype in 95.9% of ST361 genomes, which we show contributes to virulence in UTI and catheter-associated UTI mouse models. Analysis of the mobile genetic elements harbouring bla NDM-5 in ST361 and other CREC further reveals a dynamic interplay between plasmid transfer and insertion elements that contributes to bla NDM-5 dissemination. Together, these findings identify ST361 as an emerging UTI-associated CREC clone and reveal the convergence of clonal expansion, virulence-associated surface architecture and mobile genetic elements in its spread.

  • A Randomized Controlled Trial of Cefiderocol Versus Standard Therapy for Gram-negative Bacterial Bloodstream Infections: Benefit and Risk Assessment Using Desirability of Outcome Ranking and Generalized Pairwise Comparisons

    by Melissa J Hardy, Patrick N A Harris, Yin Mo, Mark D Chatfield, Helmi Sulaiman, Po-Yu Liu, Mesut Yilmaz, Zeti Norfidiyati Salmuna, Mohd Zulfakar Mazlan, Siriluck Anunnatsiri, et al.

    Background: Gram-negative bacterial bloodstream infections (BSIs) cause substantial mortality and morbidity. The GAME CHANGER trial compared cefiderocol with standard of care (SOC) for Gram-negative BSIs, with 14-day all-cause mortality (ACM) as the primary endpoint. We evaluated cefiderocol versus SOC integrating efficacy and safety outcomes using desirability of outcome ranking (DOOR) and generalized pairwise comparisons (GPC). Methods: Composite endpoints were prespecified before data review. The DOOR endpoint included treatment failure, infectious complications, serious adverse events, and 90-day ACM, with functional improvement as a tiebreaker. The GPC approach included ACM at 30 days, clinical failure, serious adverse events, functional improvement, and hospitalization duration. Analyses were conducted in the main population and carbapenem-resistant subset. Results: The DOOR composite in the main population resulted in a probability of a more desirable outcome with cefiderocol of 50.4% (95% confidence interval [CI], 45.6–55.1). The analysis with GPC resulted in a win ratio and win odds of 1.04 (95% CI, 0.85–1.28) and net treatment benefit of 2.1% (95% CI, −8.0 to 12.2). In the carbapenem-resistant subset, the DOOR probability with cefiderocol was 46.8% (95% CI, 37.4–56.1). The analysis with GPC resulted in a win ratio and win odds of 0.90 (95% CI, 0.60–1.34) and net treatment benefit of −5.4% (95% CI, −25.3 to 14.5). Conclusions: In adults with Gram-negative bacterial BSIs, cefiderocol was not superior to SOC based on DOOR or GPC analyses in both the main population and carbapenem-resistant subset. Integrating efficacy, safety, and functional outcomes using these approaches provides a more comprehensive assessment than mortality alone.

  • Open Access

    Evaluating the efficiency of platform trials relative to stand-alone trials: a simulation study for the evaluation of new antibacterials

    by Melissa J Hardy, Patrick N A Harris, Xiaofang Wang, Yin Mo, David L Paterson

    Background: Serious Gram-negative bacterial infections impose significant burden, with carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant Enterobacterales designated as WHO critical priority pathogens. Antibacterial registration trials are traditionally stand-alone two-arm randomized controlled trials evaluating one agent in a site-specific infection. Platform trials have been proposed as an alternative to identify new treatments more efficiently. Objectives: To evaluate the efficiency of different trial designs for treatments in serious resistant Gram-negative infections. Methods: We conducted simulation studies comparing platform trials with parallel and staggered starts and multiple stand-alone trials for serious infections caused by critical priority Gram-negative pathogens. Simulated recruitment and randomization were used to assess the impact of trial design, control type and allocation ratio on trial duration, sample size and operating characteristics. Results: In this setting, parallel or staggered platform trials reduced the sample size by 31–279 participants and the trial duration by 7–13 months compared with stand-alone trials. The staggered platform trial with concurrent controls required 11.0%–23.4% fewer participants and up to 46.8% less control participants than stand-alone trials. Across designs and scenarios, type I error and power, were consistently close to the nominal levels for all treatment-control comparisons. Conclusions: Platform trials can improve efficiency over stand-alone trials, reducing duration and sample size while maintaining operating characteristics. The improvement varies with control type, allocation ratio and staggered entry of agents and could help accelerate antibacterial development. This has implications for funders, sponsors and patients requiring access to new therapies, while recognizing ongoing operational and regulatory challenges.


  • Open Access

    Novel transposon Tn8026 contributes to the global spread of transmissible linezolid resistance in Enterococcus via a linear plasmid

    by Michael B. Hall, Yiyang Xue, Tricia S.E. Lee, Ella Herring, Jocelyn Hume, Ryan R. Wick, Timothy Kidd, Naomi Runnegar, Patrick N. A. Harris, Bianca Graves, et al.

    Linezolid is a critical last-resort antimicrobial for multidrug-resistant Enterococcus faecium , particularly against vancomycin-resistant lineages where therapeutic options are severely limited. While resistance has historically arisen through de novo chromosomal mutations, the global emergence of transferable resistance mechanisms threatens to render more infections untreatable. Here, we characterize a recent (2023–2024) hospital-associated outbreak of linezolid-resistant E. faecium in Queensland, Australia. Although the cohort comprised a variety of sequence types, the outbreak was primarily driven by the clonal expansion of an ST80 lineage carrying the plasmid-borne poxtA gene. Standard short-read genomic surveillance failed to resolve the genetic context of the resistance determinant. However, long-read sequencing revealed that poxtA was carried within a novel transposon, Tn 8026 , situated on a linear plasmid. Structural analysis defined Tn 8026 as a unique element flanked by IS 1678 and the novel insertion sequence IS Efa26 . Furthermore, we identified an instance of Tn 8026 integration into the chromosome, providing functional evidence of its mobility and capacity for stabilization within the genome. Global genomic screening demonstrated that Tn 8026 significantly predates the local outbreak, identified in a historical Norwegian isolate from 2012, indicating a long-standing yet unrecognized global reservoir. Phylogenomic analysis provided strong evidence that the linear plasmid was imported from the Indian subcontinent, initiating a chain of silent dissemination in eastern Australia where the lineage circulated undetected prior to clinical recognition. Crucially, we also confirmed the presence of the linear plasmid in Enterococcus gallinarum , demonstrating its capacity to mobilize transmissible linezolid resistance across enterococcal species boundaries. These findings emphasize the need for detailed long-read-based surveillance of mobile genetic elements, with a particular focus on identifying linear plasmids that are often overlooked.


  • Implementation of pathogen genomics in clinical microbiology laboratories

    by Andrew P. Gador-Whyte, Norelle L. Sherry, Anna Brischetto, Patiyan Andersson, Katherine A. Bond, Sebastiaan J. van Hal, Patrick N. A. Harris, Benjamin P. Howden, On Behalf Of The Australian Pathogen Genomics Program Partners

    SUMMARY: Pathogen genomics, including whole-genome sequencing (WGS) and clinical metagenomics, is a transformative technology increasingly being implemented in clinical microbiology, including in hospital laboratories. Pathogen genomics can improve the control of healthcare-associated infections, provide rapid infection diagnosis, and could enable replacement of laborious microbiology tests. To date, real-world implementation of pathogen genome sequencing has primarily been limited to public health laboratories, but sequencing in the clinical microbiology setting has the potential to provide advantages, including turnaround time and ability to focus on local priorities. In this review, we consider the factors that represent barriers to, and potential enablers of, the implementation of pathogen genomics in clinical microbiology, including the availability of funding and genomics-trained staff. We outline key use cases and implementation models of pathogen genomics in clinical microbiology and suggest a broad framework for labs commencing sequencing. Finally, we consider future opportunities, including direct-from-specimen sequencing, the role of machine learning in genomics analysis, and the application of pathogen genomics to clinical decision support.


  • Open Access

    Development and validation of a real-time polymerase chain reaction for the detection of Haycocknema perplexum

    by Kym Lowry, Bijendra Parmar, Rita Gupta, Thomas Robertson, David Whiley, Patrick N.A. Harris, Natalie Davidson

  • Open Access

    Emulating a target trial of early compared with late initiation of appropriate antibiotic therapy for hospital-acquired monobacterial Gram-negative bloodstream infections.

    by Abdullah T Aslan, Yukiko Ezure, Elif Seren Tanriverdi, Osman Dağ, Cansu Cimen, Ayşe Kaya Kalem, Bircan Kayaaslan, Sevil Alkan, Bahadır Köylü, Emine Büşra Ata, et al.

    Delays in appropriate antimicrobial therapy can increase the risk of all-cause mortality (ACM) in hospital-acquired bloodstream infections (HA-BSIs) caused by Gram-negative bacteria (GNB). We aimed to evaluate the effectiveness of early appropriate antimicrobial therapy (EAAT) compared with late appropriate antimicrobial therapy (LAAT) in this population. This study used data from a multi-centre, prospective cohort including adult patients with HA-BSI caused by GNB across 22 Turkish hospitals. A hypothetical target trial allocating participants with HA-BSI caused by monobacterial GNB to either EAAT or LAAT was emulated using the weighting approach. The primary outcome was 14 day ACM; 28 day ACM was a secondary outcome. Cox proportional hazards models with inverse probability weighting were applied to account for confounding, with antibiotic treatment incorporated as a time-dependent variable. Among 680 patients, 14 day ACM occurred in 14.7% (40/272) of the EAAT group and 42.9% (175/408) of the LAAT group. EAAT was associated with a lower risk of 14 day ACM [adjusted hazard ratio (aHR) = 0.41; 95% CI: 0.28-0.61). Similarly, 26.1% (71/272) of the patients treated with EAAT and 49.5% (202/408) of those receiving LAAT died during 28 day follow-up (aHR = 0.66; 95% CI: 0.50-0.86). In the carbapenem-resistant GNB subset, EAAT reduced the hazard of 14 day ACM (aHR = 0.36; 95% CI: 0.21-0.60) and 28 day ACM (aHR = 0.60; 95% CI: 0.44-0.84). All prespecified and post hoc analyses consistently supported these findings. EAAT was associated with a survival benefit in individuals with HA-BSI due to GNB. Although these findings support early initiation of appropriate therapy, residual confounding cannot be excluded.


  • Top Cited Papers
    Open Access

    Carbapenemases: epidemiology, detection and management in a changing global landscape

    by Nenad Macesic, Patrick N A Harris, Yin Mo, Angela Gomez-Simmonds

    Carbapenemase-producing Gram-negative bacteria are a growing threat to last-line beta-lactam (BL) therapy and are now established across Enterobacterales, Pseudomonas aeruginosa and Acinetobacter baumannii. Since the first reports in the 1980s, carbapenemase genes have disseminated internationally through plasmids, transposons and integrons and have become embedded in high-risk clones, with contemporary epidemiology dominated by Klebsiella pneumoniae carbapenemases (KPC), New Delhi metallo-beta-lactamase, Verona integron-encoded, imipenemase and oxacillinase (OXA)-type enzymes. The past decade has been marked by spread beyond hospitals, rising metallo-beta-lactamase (MBL) prevalence, and convergence of resistance with hypervirulence in some lineages. This Review summarizes carbapenemase classification, genetic contexts and epidemic clones. It describes regional distribution patterns alongside One Health drivers linking healthcare, community, animal and environmental reservoirs. We outline a pragmatic diagnostic framework spanning screening, confirmatory phenotypic assays, rapid lateral flow and molecular platforms, and whole genome sequencing for surveillance and outbreak investigation, emphasizing the clinical value of early mechanism identification for both infection control and targeted therapy. Treatment is reviewed in a mechanism-directed manner: newer BL/beta-lactamase inhibitor combinations are central for serine carbapenemases (including KPC and many OXA-48-like producers), whereas MBL producers require alternative strategies such as aztreonam-based combinations or cefiderocol. Options remain limited for carbapenemase-producing P. aeruginosa and A. baumannii, although sulbactam-durlobactam and pipeline agents are expanding the therapeutic landscape. We highlight the widening gap between disease burden and access to rapid diagnostics and novel therapies, particularly in high-burden low- and middle-income settings. Finally, we outline the bundled infection prevention and antimicrobial stewardship interventions needed to contain transmission and preserve the effectiveness of novel agents.


  • Open Access

    Implementation of the BIOFIRE Meningitis/Encephalitis Panel: A Mixed-Methods Implementation Study in a Nonmetropolitan Tertiary Hospital

    by Shradha Subedi, N A Patrick Harris, Lisa Hall, L David Paterson

    Background: Meningitis and encephalitis (ME) are associated with significant morbidity and mortality. Rapid pathogen identification is essential to guide early treatment and support antimicrobial stewardship (AMS). The BIOFIRE® FILMARRAY® ME panel allows simultaneous detection of multiple pathogens from cerebrospinal fluid. This study evaluated the implementation strategy and clinician adoption of the panel in a large nonmetropolitan tertiary hospital in Australia Method: A mixed-methods study was conducted at the Sunshine Coast University Hospital following implementation of the BIOFIRE ME panel. Strategies included education sessions, testing criteria development, and continuous stakeholder engagement. Clinician knowledge, confidence, and antimicrobial decision-making practices were assessed at baseline and during implementation via surveys and semistructured interviews based on the Cabana et al conceptual framework. Quantitative data were analyzed using descriptive statistics, while qualitative data were analyzed thematically using Braun and Clarke's 5 step process. Results: A total of 213 clinicians participated in the surveys across 4 time points. Median perceived usefulness of rapid CSF PCR testing was 9/10. Confidence in ceasing antibiotics based on the assay results increased from 18% at 9 months to 52% at 12 months (P = .06), while confidence in ceasing antivirals remained high (85%–86%). Qualitative findings identified 5 themes influencing implementation: test-ordering practices, perceived diagnostic value, trust in results, antimicrobial stewardship, and behavioral change. Confidence in interpretation was highest where infectious diseases input was available. Conclusions: Implementation of the syndromic panel improved diagnostic efficiency and clinician confidence in antimicrobial decision making. Sustained education, multidisciplinary collaboration, and integration of stewardship frameworks were key to achieving successful adoption.